https://www.selleckchem.com/pr....oducts/l-selenomethi
The Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) was developed to incorporate the patient's perspective into evaluation of clinical benefit in advanced non-small cell lung cancer trials and meet regulatory expectations for doing so. Qualitative evidence supported 7 items covering 5 symptom concepts. This study evaluated measurement properties of the NSCLC-SAQ's items, overall scale, and total score. In this observational cross-sectional study, a purposive sample of patients with clinician-diagnosed
Aimer
Commentaire
Partagez
